Provident Data Centers Joins Texas Nuclear Alliance as Founding Member
'Provident is leading the way in developing the data centers our always-advancing society need, and nuclear energy offers a reliable, safe, carbon-free power source to meet the industry's energy demands,' said TNA President Reed Clay. 'We can expect the data center and nuclear energy industries to continue working together as our state, nation and world demands more of both.'
'Provident Data Centers was founded in Texas, built in Texas, and is proud to help power Texas into its next chapter. As the first and currently only data center developer to join the Texas Nuclear Alliance's governing board, we fully support Governor Abbott's vision for Texas to lead the nation in AI and energy reliability. We believe safe, firm, carbon-free nuclear energy is foundational to achieving these goals,' said Jack Backes, Principal Strategist for Provident Data Centers.
'We're hopeful the Texas Senate will pass House Bill 14 to establish a state nuclear office and unlock vital funding for the first wave of nuclear construction and supply chain development in decades. Visionary leadership backed by intelligent, long-term investment is exactly what this moment demands. With 40 years of development experience in Texas, Provident is investing in next-generation energy ecosystems —including organizations like the Texas Nuclear Alliance — that strengthen grid stability, support statewide data center infrastructure, and help power Texas' industrial growth,' Backes continued.
About Provident Data Centers
Provident Data Centers, headquartered in Dallas, TX is a community-driven data center developer dedicated to building 'win-win' partnerships with clients and communities. As a division of Provident, a privately held leading real estate and investment firm, Provident Data Centers brings over three decades of real estate development experience to create cutting-edge data centers for enterprise, hyperscale, and telecom clients. This expertise currently spans six states, with over 50 buildings delivering more than +6 GW of planned and committed power. Provident Data Centers streamlines the development process by managing site selection, land acquisition, design and construction, and infrastructure build-out. This comprehensive approach ensures smooth project execution, minimizes risks, and delivers positive outcomes for all stakeholders. With vast industry knowledge, Provident Data Centers brings a transparent approach and continues to focus on innovative, efficient, and scalable solutions for an evolving digital landscape. To learn more, visit www.providentdatacenters.net and follow on LinkedIn.
About the Texas Nuclear Alliance
TNA is the only industry association in Texas dedicated to the advancement of nuclear technology in the state. TNA was formed with a singular mission: to make Texas the Nuclear Capital of the World. Formed in 2022 in the aftermath of Winter Storm Uri, TNA is based on the fundamental premise that if Texas and the world want low-carbon, reliable energy, it can no longer turn its back on nuclear energy. Nuclear is clean, safe, reliable, and secure.
Contact Information:
Texas Nuclear Alliance
Lauren Clay
512-567-7604
Contact via Email
www.texasnuclearalliance.org
Read the full story here: Provident Data Centers Joins Texas Nuclear Alliance as Founding Member
Press Release Distributed by PR.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
Key Points AbbVie has performed better than the market over the past decade. The company has lost a major product, but its lineup and pipeline remain strong. AbbVie still has a solid business and boasts a strong dividend program. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate greater shareholder value by focusing on its main area of expertise, which, for AbbVie, is the development and marketing of pharmaceutical products. Did the move produce the desired effect? One way to determine whether it has is to check AbbVie's performance over the past decade against that of the broader market. Let's look into that, and also try to determine if AbbVie is a worthwhile investment. It's been a terrific investment Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's significantly better than the performance of the S&P 500. If you had invested $1,000 in AbbVie 10 years ago, you'd have $4,530.75, compared to just $3,690.99 for the S&P 500. How did AbbVie manage to pull that off? The most important asset the company had through this period was its immunology drug Humira. In the U.S. alone, it has been approved for 12 indications, including Crohn's disease, psoriatic arthritis, and plaque psoriasis. The medicine's sales consistently grew at a good clip, helping AbbVie generate stable financial results. The drugmaker hit a speed bump in 2018, when Humira's patent expired in Europe and the company faced biosimilar competition there. Revenue from the blockbuster medicine dropped slightly, but due to continued momentum in the U.S., its sales began moving in the right direction again. Humira went on to become the best-selling medicine in the history of the industry, hitting a peak of $22.1 billion before losing patent protection in the U.S. in 2023. The future is still bright What's next for AbbVie, now that it's effectively lost the most important asset that allowed it to perform so well after splitting from Abbott? The company is moving on thanks to two other immunology products, Skyrizi and Rinvoq. Both were first approved in the U.S. in 2019 and have since won various label expansions. Together, Skyrizi and Rinvoq significantly overlap with Humira's indications; in some cases, they're more effective than their predecessor. For instance, one study found that Skyrizi was more effective than Humira in plaque psoriasis. Between them, Skyrizi and Rinvoq should more than fill Humira's shoes. Management predicts that the two will combine for $31 billion in sales by 2027, significantly surpassing the $22.1 billion Humira achieved at its peak. And AbbVie's next-generation immunology superstars should continue growing their sales for a long time after that -- they haven't even been on the market for a decade yet. That all paints a bright picture for the company's future, especially when considering the rest of its business. AbbVie closed its acquisition of Allergan for $63 billion in 2020, gaining access to key products, including its Botox franchise and schizophrenia treatment Vraylar. AbbVie's lineup features a range of other medicines that are helping drive top-line growth, such as Qulipta for migraine, and cancer drug Venclexta. The company also has a deep pipeline and routinely expands it thanks to acquisitions or licensing deals. In March, it announced an agreement with Denmark-based Gubra A/S for the development of GUB014295, for weight management, an area of the pharmaceutical industry that's catching fire. This move may or may not pan out, but AbbVie's extensive pipeline should allow it to replenish its lineup before it has to deal with patent cliffs for Skyrizi and Rinvoq. Lastly, AbbVie is an excellent dividend payer. The company has increased its payouts by 221.6% over the past decade and stands as one of the Dividend Kings, with 53 consecutive years of payout increases, including the time it spent under the wing of its former parent company. AbbVie also offers a juicy forward yield of 3.2%, much higher than the S&P 500's average of 1.3%. AbbVie isn't done beating the market: The stock could still deliver over the next decade, especially for those who opt to reinvest the dividend. Should you buy stock in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
4 days ago
- Yahoo
Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion
The HIV Diagnostics Companies Quadrant report offers an in-depth analysis of the global HIV diagnostics market, assessing over 100 companies and highlighting the Top 14 leaders. Market expansion is driven by rising HIV/AIDS prevalence, point-of-care technological advancements, and awareness campaigns. However, high costs and skilled technician shortages hinder growth. North America leads in market dominance due to its HIV/AIDS prevalence and advanced technologies, while Asia Pacific is projected to grow fastest. Key players like Abbott, Siemens Healthineers, and Thermo Fisher Scientific employ strategies like acquisitions and innovations to maintain strong market positions amid evolving trends. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "HIV Diagnostics - Company Evaluation Report, 2025" report has been added to HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV Diagnostics Companies were categorized and recognized as the quadrant growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this Players:Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this (US)Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Healthineers AG (Germany)Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector Fisher Scientific (US)With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Prevalence of Hiv/Aids3.2.1.2 Increasing Number of Blood Transfusions & Blood Donations3.2.1.3 Advantages Offered by Poc Diagnostic Kits & Instruments3.2.1.4 Increasing Initiatives for Hiv Awareness Campaigns3.2.2 Restraints3.2.2.1 High Cost of Nats3.2.3 Opportunities3.2.3.1 High Growth Potential of Emerging Economies3.2.3.2 Trend of Self-Testing and Growing Preference for At-Home Diagnostic Kits3.2.4 Challenges3.2.4.1 Operational Barriers and Shortage of Skilled Laboratory Technicians3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.5 Supply Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Elisa3.7.2 Complementary Technologies3.7.2.1 Western Blot Tests3.7.3 Adjacent Technologies3.7.3.1 Pcr3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Forces Analysis3.10.1 Threat of New Entrants3.10.2 Threat of Substitutes3.10.3 Bargaining Power of Buyers3.10.4 Bargaining Power of Suppliers3.10.5 Intensity of Competitive Rivalry3.11 Impact of Ai/Generative Ai on Hiv Diagnostics Market3.11.1 Market Potential of Ai in Hiv Diagnostics3.11.2 Ai Use Cases3.11.3 Company Implementation of Ai3.11.4 Future of Ai/Generative Ai4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Hiv Diagnostics Market4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.4.1 Ranking of Key Market Players4.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Product Footprint4.5.5.4 End-User Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Smes4.7 Company Valuation & Financial Metrics4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product/Service Launches & Approvals4.9.2 Product Launches & Approvals4.9.3 Deals4.9.4 Expansions4.9.5 Other Developments5 Company Profiles Abbott Siemens Healthineers Grifols, S.A. Danaher Corporation Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Biomerieux Hologic, Inc. Qiagen Bd Trinity Biotech Orasure Technologies, Inc. Biosynex Sa Wondfo Getein Biotech, Inc. Meril Life Sciences Pvt. Ltd. Accubiotech Co., Ltd. Biolytical Laboratories Inc. Bio Lab Diagnostics (I) Private Limited Alpine Biomedicals Pvt Ltd. Molbio Diagnostics Pvt. Ltd. Fortress Diagnostics Advacare Pharma (Accuquik) Adaltis S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Associated Press
Westinghouse Joins the Texas Nuclear Alliance as a Founding Member
Austin, TX August 12, 2025 --( )-- The Texas Nuclear Alliance (TNA) proudly welcomes Westinghouse Electric Company, a global leader of advanced nuclear technologies, as a Founding Member. Westinghouse innovations cover the complete nuclear lifecycle, from proven reactor technologies for power plants and next-generation reactor designs to nuclear fuel products and plant operation services and solutions. 'Westinghouse has unmatched nuclear expertise, providing the technology that is used to run nearly half of the world's operating nuclear plants, including the four commercially operating reactors at South Texas Project and Comanche Peak here in Texas,' said TNA President Reed Clay. 'TNA is proud to partner with Westinghouse to ensure safe and reliable nuclear energy continues to power future generations here in Texas.' 'TNA is providing bold leadership to bring the benefits of reliable, abundant and clean nuclear energy to Texans,' said Dan Sumner, Interim Chief Executive Officer, Westinghouse. 'As a company that has been a part of the Texas nuclear ecosystem for decades, Westinghouse stands ready to help the state explore new opportunities – whether it is proven grid-scale technologies like our AP1000® reactor, our AP300™ small modular reactor (SMR) or flexible next-generation innovations like our eVinci® microreactor.' The fully licensed and construction-ready advanced AP1000® reactor is the only operating Generation III+ reactor with fully passive safety systems, modular construction and the smallest footprint per MWe on the market. There are six AP1000 reactors currently setting operational performance and availability records worldwide with twelve additional reactors under construction and six more under contract. Based on proven AP1000 technology, the AP300 SMR is the world's most advanced and deployable SMR solution. Unlike every other SMR under development with first-of-a-kind technologies, the AP300 SMR uses AP1000 engineering, components and supply chain to reduce deployment risks. The eVinci microreactor builds on decades of industry-leading Westinghouse innovation to bring resilient, secure and scalable energy wherever it is needed. The eVinci microreactor has few moving parts, working essentially as a battery, providing the versatility for power systems ranging from several kilowatts to 5 megawatts of electricity, delivered 24 hours a day, 7 days a week for eight-plus years without refueling. About Westinghouse Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear and other clean power technologies and services globally. Westinghouse supplied the world's first commercial pressurized water reactor in 1957 and the company's technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation makes Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit About the Texas Nuclear Alliance TNA is the only industry association in Texas dedicated to the advancement of nuclear technology in the state. TNA was formed with a singular mission: to make Texas the Nuclear Capital of the World. Formed in 2022 in the aftermath of Winter Storm Uri, TNA is based on the fundamental premise that if Texas and the world want low-carbon, reliable energy, it can no longer turn its back on nuclear energy. Nuclear is clean, safe, reliable, and secure. Contact Information: Texas Nuclear Alliance Lauren Clay 512-567-7604 Contact via Email Westinghouse Paul Erwin [email protected] Read the full story here: Westinghouse Joins the Texas Nuclear Alliance as a Founding Member Press Release Distributed by
